The effectiveness of immunosuppressive therapy in patients with aplastic anaemia secondary to chemoradiotherapy for cancers.
aplastic anaemia
cancer
chemoradiotherapy
glycosylphosphatidylinositol-anchored protein-deficient cells
immunosuppressive therapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
15
05
2021
accepted:
14
08
2021
pubmed:
4
9
2021
medline:
4
1
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
The outcome of immunosuppressive therapy (IST) and prognosis in patients with aplastic anaemia (AA) secondary to chemotherapy or radiotherapy for cancers remains unknown. A total of 43 of 2559 patients with AA referred to our hospital had previously received chemoradiotherapy for various types of solid tumours (n = 25) or haematological malignancies (n = 18). Their cancer status was complete remission (CR) in 27, non-CR in 13, and unknown in three. Small populations of glycosylphosphatidylinositol-anchored protein-deficient [GPI(-)] granulocytes were detected in 16 patients (37·2%). Of 18 patients who were treated with IST, 50% improved regardless of the presence of GPI(-) cells. The overall survival (OS) rate was significantly higher in patients with a history of solid tumours patients than in those of haematological malignancies (median OS, 87 vs. 11 months, P = 0·0003), and in patients treated with IST than in those of untreated patients (median OS, 115 vs. 20 months, P = 0·028). Cancer aggravation occurred in two of four patients who were treated with IST while in non-CR of their original cancers. Progression to myelodysplastic syndromes was observed in two patients not possessing GPI(-) cells. IST should thus be considered for patients with AA secondary to chemoradiotherapy for cancers, particularly when their original solid tumours are in CR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
770-780Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643-56.
Fianchi L, Pagano L, Piciocchi A, Candoni A, Gaidano G, Breccia M, et al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol. 2015;90:E80-E85.
Sugimori C, Mochizuki K, Qi Z, Sugimori N, Ishiyama K, Kondo Y, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol. 2009;147:102-12.
Fattizzo B, Ireland R, Dunlop A, Yallop D, Kassam S, Large J, et al. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01190-9 [Online ahead of print].
Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-14.
Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373:35-47.
Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897-902.
Camitta BM. What is the definition of cure for aplastic anemia? Acta Haematol. 2000;103:16-8.
Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, Noji H, Shichishima T, et al. Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. Ann Hematol. 2018;97:2289-97.
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452-8.
Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res. 2018;71:95-9.
Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJ, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 2019;5:318-25.
Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234-41.
Uchida A, Mizutani Y, Nagamuta M, Ikenaga M. Effects of X-ray irradiation on natural killer (NK) cell system. II. Increased sensitivity to natural killer cytotoxic factor (NKCF). Immunopharmacol. Immunotoxicol. 1989;11:521-34.
Halpern JN, Cohen E, Mekori T, Beny AN, Kuten A, Rosenblatt EA, et al. The effect of in vitro irradiation on human NK cell activity. A preliminary report. J Med. 1991;22:243-54.
Swerdlow SH, editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC; 2017.
Hosokawa K, Katagiri T, Sugimori N, Ishiyama K, Sasaki Y, Seiki Y, et al. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation. Haematologica. 2012;97:1845-9.
Sugimori N, Yamazaki H, Sugimori C, Ishiyama K, Katagiri T, Nakao S. Clinical significance of chromosomal abnormalities in patients with aplastic anemia and refractory anemia deduced from the prevalence of PNH-type cells. Blood. 2009;114:1085.
Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, et al. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res. 2011;35:863-7.
Hosokawa K, Sugimori N, Katagiri T, Sasaki Y, Saito C, Seiki YU, et al. Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. Eur J Haematol. 2015;95:230-8.
Ishiyama K, Chuhjo T, Wang H, Yachie A, Omine M, Nakao S. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2003;102:1211-6.